Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An Innovative Approach for Increasing Access to Over-the-Counter Hearing Aids in Rural Communities of Alabama.

Seminars in hearing·2025

Same author

Current and Future Opportunities and Challenges in Continuing Pharmacy Education: A 2024 Update.

American journal of pharmaceutical education·2024

Same author

Enzymatic Stability of Alteplase Solution for Injection: Effect of Various Methods of Thawing Frozen Solutions.

Hospital pharmacy·2024

Same author

A Continuing Pharmacy Education (CPE) Program Assessing Cannabidiol (CBD) Knowledge and Confidence Among Practicing Pharmacists.

Journal of pharmacy practice·2023

Same author

Principles for Continuing Professional Development (CPD) Programs: A Statement by the ACPE CPD Advisory Committee.

American journal of pharmaceutical education·2023

Same author

Genomic regulation of Krüppel-like-factor family members by corticosteroid receptors in the rat brain.

Neurobiology of stress·2023

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Dronedarone: an alternative to amiodarone?

Peter J Hughes¹, Maisha Kelly Freeman, Frances V Cohenour

¹Samford University Global Drug Information Service, Birmingham, Alabama 35229, USA. pjhughes@samford.edu

The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists

|September 30, 2010

Summary

Dronedarone offers a safer profile than amiodarone for atrial fibrillation patients, though it is less effective and more costly. It is a niche alternative for those intolerant to amiodarone.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Experiment Videos

Last Updated: Jun 8, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Area of Science:

Pharmacology
Cardiology
Clinical Trials

Background:

Dronedarone is a newly approved antiarrhythmic drug.
It is a derivative of amiodarone, a widely used antiarrhythmic.
Dronedarone was developed to offer a potentially safer alternative to amiodarone.

Purpose of the Study:

To compare the safety and efficacy of dronedarone against amiodarone.
To evaluate dronedarone as a potential therapeutic alternative for amiodarone.

Main Methods:

Searched MEDLINE/PUBMED and International Pharmaceutical Abstract databases.
Included human studies of dronedarone, alone or with amiodarone.
Reviewed English language papers and bibliographic references.

Main Results:

Dronedarone is approved for reducing hospitalizations in atrial fibrillation/flutter.
It has a lower risk of pulmonary, thyroid, and dermatologic adverse effects than amiodarone.
Dronedarone showed poorer bioavailability, a shorter half-life, and no superiority in preventing atrial fibrillation recurrence compared to amiodarone.
Dronedarone therapy is more expensive and increases tablet burden.
No serious organ toxicities reported for dronedarone; no dosage adjustment for renal impairment, contraindicated in severe hepatic impairment.

Conclusions:

Dronedarone may serve as a niche alternative for patients intolerant to amiodarone or with contraindicating comorbidities.
Dronedarone's safety profile regarding thyroid and pulmonary systems is favorable.
Extensive research is lacking on dronedarone for many indications and populations where amiodarone is used.